Diabetes Research

At the American Diabetes Association's 2026 Scientific Sessions in New Orleans, tech updates were focused on making diabetes care more accessible and less disruptive.

People with type 1 diabetes are making insulin again through experimental and FDA-approved treatments. What challenges remain in order to make these transplants safe and widely accessible?

Big new insights on diabetes treatments and technology emerged from the American Diabetes Association’s (ADA) 2026 conference in New Orleans. Here’s what matters most for people living with diabetes.

Survodutide is a new investigational dual GLP-1 injectable medication being tested for weight management in clinical trials.

Results from recent clinical trials suggest that retatrutide, a first-of-its-kind experimental drug, causes unprecedented levels of weight loss. Its effects on blood sugar for diabetes are comparable to currently available GLP-1 drugs like Ozempic. 

A clinical trial is recruiting children, teens, and adults recently diagnosed with stage 3 type 1 diabetes to test a new drug designed to slow disease progression indefinitely.